1	MDA5 variants trade antiviral activity for protection from autoimmune
2	disease
3	Chris Wallace <sup>1,2,*</sup> , Rahul Singh <sup>1,3</sup> , Yorgo Modis <sup>1,3,*</sup>
4	<sup>1</sup> Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of
5	Cambridge School of Clinical Medicine, Cambridge, UK
6	<sup>2</sup> MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
7	<sup>3</sup> Molecular Immunity Unit, Department of Medicine, University of Cambridge, MRC Laboratory of
8	Molecular Biology, Francis Crick Avenue, Cambridge, UK
9	*Correspondence: C.W., <u>cew54@cam.ac.uk;</u> Y.M., <u>ymodis@mrc-Imb.cam.ac.uk</u>
10	
11	Keywords: Type 1 diabetes (T1D); inflammatory bowel disease (IBD); human genetic variants;
12	Genome-wide association studies (GWAS); fitness trade-off; autoimmune disease
13	
14	Running title: MDA5 variants trade T1D protection for IBD risk

#### 15 Abstract

Loss-of-function variants in MDA5, a key sensor of double-stranded RNA from viruses and 16 17 retroelements, have been associated with protection from type 1 diabetes (T1D) in genome-18 wide association studies (GWAS). MDA5 loss-of-function variants have also been reported to 19 increase the risk of inflammatory bowel disease (IBD). Whether these associations are linked or 20 extend to other diseases remains unclear. Here, fine-mapping analysis of four large GWAS 21 datasets shows that T1D-protective loss-of-function MDA5 variants also protect against 22 psoriasis and hypothyroidism, while increasing the risk of IBD. The degree of autoimmune 23 protection and IBD risk were linearly proportional. The magnitudes of the odds ratios for 24 autoimmune protection and IBD risk were larger for rare MDA5 variants than for common 25 variants, which were differentially expressed in different geographic populations. Our analysis 26 suggests MDA5 genetic variants offer a direct fitness trade-off between viral clearance and 27 autoimmune tissue damage.

28

#### 29 Introduction

30 Innate immune responses must be sensitive enough to detect infection yet specific enough to 31 avoid activation by cellular components. A key innate immune receptor for cytosolic doublestranded RNA (dsRNA), a potent signature of viral infection, is MDA5<sup>1-5</sup>. Recognition of dsRNA 32 by MDA5 induces a potent IFN- $\beta$  response<sup>2,3</sup>. The ATPase activity and dsRNA binding 33 34 cooperativity of MDA5 confer the necessary sensitivity and specificity of MDA5-dsRNA 35 recognition<sup>4-6</sup>. Mutations in the gene encoding MDA5, *IFIH1*, can perturb the balance between 36 sensitive and specific dsRNA recognition. IFIH1 is a hotspot for natural variants with clinical 37 associations. Approximately 40 gain-of-function missense variants have been associated with 38 interferonopathies<sup>7-9</sup>. These variants promote formation of MDA5 signaling complexes, including 39 on endogenous dsRNAs, by either increasing the RNA binding affinity of MDA5 or inhibiting its

40 ATP-dependent proofreading activity <sup>5,9,10</sup>. Loss-of-function MDA5 variants cause recurrent 41 infections<sup>11</sup>, and have been reported to contribute to inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease<sup>12,13</sup>. GWAS data have also associated loss-of-42 43 function MDA5 variants with reduced risk of developing certain autoimmune diseases, most notably T1D<sup>14-19</sup>. Specifically, variants E627\* (rs35744605), R843H (rs3747517), I923V 44 (rs35667974), and T946A (rs1990760) have been identified as T1D-protective<sup>14-18,20,21</sup>. The 45 46 E627\* and I923V variants are rare, with allele frequencies of 1-2%, while R843H and T946A are 47 common. These common variants are differentially expressed in different geographic 48 populations. The T946A variant is present in 70-80% of Africans and Asians but only 30-50% of Caucasians<sup>15-18,20</sup>. Similarly, the R843H variant is found in 70% of Asians but only 30-40% of 49 50 Caucasians and Africans<sup>15-18,20</sup>. Most human *IFIH1* reference sequences contain the alleles that 51 are most common in Asians (Ala946/His843). These coding variants inhibit the formation of MDA5-dsRNA signaling complexes<sup>18,22</sup> by reducing the RNA binding affinity of MDA5 or 52 hyperactivating its ATPase activity<sup>23</sup>. Other loss-of-function variants are splice donor variants 53 that reduce splicing efficiency and hence mRNA levels<sup>19</sup>. 54

55 A robust clinical link has emerged between T1D onset and recent infection with RNA viruses, in particular coxsackieviruses and other enteroviruses<sup>24</sup>. T1D patients have more 56 57 frequent and persistent enterovirus infections, which precede the appearance of prediabetic markers, including autoantibodies<sup>25</sup>. MDA5 recognizes RNA from *Picornaviridae*, including 58 59 enteroviruses<sup>1,26</sup>, which have evolved mechanisms to suppress IFN- $\beta$  transcription<sup>27,28</sup>. MDA5-60 induced inflammation in the pancreas following rotavirus infection contributes to autoimmune destruction of pancreatic  $\beta$ -cells<sup>29</sup>. Therefore, a plausible hypothesis is that MDA5-dependent 61 62 inflammation following viral infection can trigger autoimmune  $\beta$ -cell killing.

Gastrointestinal viral infection has also been linked to IBD onset<sup>30</sup>. Intestinal cells from IBD patients harboring loss-of-function MDA5 variants had elevated viral loads and were compromised in their ability to maintain epithelial barrier integrity upon further exposure to the enteric virome<sup>13</sup>. Hence, the frequency and clinical phenotypes of MDA5 loss-of-function variants in IBD patients suggest that MDA5 deficiency contributes to the induction of IBD<sup>12,13</sup>, due in part to increased exposure and susceptibility to viral infection<sup>11,13</sup>.

#### 69 **Results and Discussion**

70 Loss-of-function MDA5 variants have been associated with recurrent infection<sup>11</sup>, T1D protection<sup>14-19</sup>, and IBD risk<sup>12,13</sup>. However, whether these associations are linked, or whether 71 72 they apply to autoimmune disease more broadly, has not been explored. We addressed these 73 guestions by utilizing larger, more recent GWAS studies to conduct a broader, more sensitive 74 survey of immune-mediated disease associations involving MDA5 variants. For our analysis, we 75 selected GWAS datasets to maximize the likelihood of accurate fine mapping - balancing the 76 need for large sample size, minimizing the use of imputed genotypes, and using ancestries that 77 best matched the reference panel used to derive linkage disequilibrium (LD) estimates<sup>31-34</sup> (see 78 Methods). By reviewing associations with a reported lead T1D-associated variant, I923V 79 (rs35667974)<sup>15</sup> we identified psoriasis, hypothyroidism, Crohn's disease, and ulcerative colitis 80 as additional associated diseases. Fine-mapping analysis using GWAS summary data for these 81 five diseases identified four variants likely to be causally associated with a subset of the 82 diseases, with considerable overlap of variants between diseases (Fig. 1, Table 1). Two of 83 these variants were coding variants, 1923V and T946A, and two were splice donor variants, 84 rs35337543 and rs35732034. All four variants were previously associated with T1D protection<sup>14-</sup> 19 85

Given the overlaps between diseases, and the small *P* values observed for fine-mapped 86 87 variants in one disease when considering another, we called associated variants by considering 88 marginal association at any of these variants or other known loss-of-function variants not in LD 89 with any of the index variants using a stringent Bonferroni correction. This identified 90 associations of a fifth variant, E627\* (rs35744605), with psoriasis, and hypothyroidism (Fig. 1). 91 While T946A is common, the other variants are rare (allele frequency below 3%). Fine-mapping 92 analysis did not find evidence for causality for variants E627\* and R843H (Table 1). However, 93 for E627<sup>\*</sup> the lack of evidence of causality is likely due to its low allele frequency (0.7%), which 94 limits power in genetics studies. In contrast, association of R843H with T1D protection is likely 95 attributable to LD with the co-occurring causal T946A allele ( $r^2 = 0.60$ ), as previously 96 reported<sup>15,16,18</sup>. Supporting these conclusions, our accompanying biochemical and structural 97 study of T1D-protective MDA5 variants shows that the E627\* variant lacks signaling activity due 98 to a loss of RNA binding affinity, whereas the R843H substitution had no effect on the structural, 99 biochemical or signaling activities of MDA5<sup>23</sup>.

100 Comparing associations across diseases, we found that all five associated variants 101 offered protection against T1D, psoriasis and hypothyroidism, but increased the risk of 102 ulcerative colitis and Crohn's disease (Fig. 2a). Remarkably, a strict correlation was observed 103 between protection and risk (Fig. 2b). A statistical test of proportionality (see Methods) 104 concluded that changes in risk were linearly proportional across variants (Fig. 2c). Additionally. 105 the magnitudes of the odds ratios were larger for the rare variants than for the common variants. 106 Thus, the rarest variant, I923V, conferred the greatest degree of T1D protection and the 107 greatest risk of IBD, whereas the most common variant, T946A, was associated with the least 108 T1D protection and IBD risk (Fig. 2a-b). Notably, the T946A variant, while common in all 109 populations, is the major allele in Asian and African populations but the minor allele in 110 Caucasians.

111 Our GWAS meta-analysis uncovers a direct correlation between protection from 112 autoimmune-related diseases (T1D, psoriasis and hypothyroidism) and increased risk of IBD. 113 The implication is that calibration of MDA5-dependent antiviral signaling offers a fundamental 114 fitness trade-off. Loss-of-function MDA5 variants protect from autoimmune tissue damage, 115 including to pancreatic  $\beta$ -cells leading to T1D, but increase the risk of inflammatory tissue 116 damage from persistent infection, including by enteric viruses in intestinal epithelia leading to 117 IBD. This model predicts that gain-of-function MDA5 variants protect from chronic inflammation 118 and IBD by ensuring infections are cleared but do so at the cost of increasing the risk of T1D 119 and other autoimmune diseases. 120 Methods 121 **GWAS** meta-analysis 122 GWAS summary data for a reported lead T1D-associated variant. I923V (rs35667974) were 123 downloaded for the following diseases: T1D (16,000 T1D cases, 25,000 controls)<sup>31</sup>; IBD (5,956 Crohn's disease cases, 6,968 ulcerative colitis cases, 21,770 controls)<sup>32</sup>; psoriasis (19,032 124 cases, 286,769 controls)<sup>33</sup>; and hypothyroidism (20,563 cases, 399,910 controls)<sup>34</sup>. Data were 125 126 downloaded from the GWAS catalog from the following repositories: ulcerative colitis, 127 https://ftp.ebi.ac.uk/pub/databases/gwas/summary statistics/GCST003001-128 GCST004000/GCST003045/harmonised/26192919-GCST003045-EFO 0000729.h.tsv.gz 129 (ImmunoChip); Crohn's disease, 130 https://ftp.ebi.ac.uk/pub/databases/gwas/summary\_statistics/GCST003001-131 GCST004000/GCST003044/harmonised/26192919-GCST003044-EFO 0000384.h.tsv.gz 132 (ImmunoChip): T1D. 133 https://ftp.ebi.ac.uk/pub/databases/gwas/summary statistics/GCST90013001-134 GCST90014000/GCST90013445/GCST90013445 buildGRCh38.tsv (ImmunoChip); Psoriasis: 135 http://ftp.ebi.ac.uk/pub/databases/gwas/summary\_statistics/GCST005001-

## 136 GCST006000/GCST005527/harmonised/23143594-GCST005527-EFO 0000676.h.tsv.gz

- 137 (Meta analysis); Hypothyroidism: https://pan-ukb-us-east-
- 138 1.s3.amazonaws.com/sumstats flat files/categorical-20002-both sexes-1453.tsv.bgz (genome
- 139 wide SNP chip). These studies were selected to balance the need for large studies and those
- 140 most likely to give accurate results in fine mapping i.e. those which minimized imputation and
- 141 most closely matched the ancestry of our reference LD panel.
- 142 Alleles were aligned to the UK Biobank as a common reference. Reference LD matrices
- 143 were estimated from 40,000 European subjects from UK Biobank. Fine mapping was performed
- 144 with a variant of the Sum of Single Effects (SuSiE)<sup>35</sup> model, as implemented in susieR<sup>36</sup>.
- 145 rs72871627 was selected as a tag ( $r^2 = 0.99$ ) of the splice donor variant rs35337543
- because rs72871627 was available in all GWAS datasets whereas rs35337543 was only
- 147 available in the T1D GWAS dataset.
- 148 Tests of proportional effects between pairs of diseases were performed across all variants in
- 149 Table X using colocPropTest [https://cran.r-project.org/package=colocPropTest] which
- 150 implements the test of proportionality as previously described<sup>37</sup>.

### 151 Data Availability

- 152 This study is a meta-analysis of previously published data. All code to reproduce this analysis is
- 153 available at Zenodo.org [https://doi.org/10.5281/zenodo.12771481].

# 154 **Competing Interests**

- 155 Y.M. is a consultant for Related Sciences LLC. The remaining authors declare no competing
- 156 interests.
- 157 Author Contributions

- 158 Conceptualization, C.E.W., R.S. and Y.M.; Methodology, C.E.W.; Formal Analysis, C.E.W. and
- 159 Y.M.; Funding Acquisition, Y.M.; Project Administration, Y.M.; Software, C.E.W.; Supervision,
- 160 Y.M.; Writing Original Draft, Y.M.; Writing Review & Editing, C.E.W., R.S. and Y.M.

## 161 Acknowledgements

- 162 We thank Louise Modis, Tetsuo Hasegawa, and the Modis group for useful discussions. This
- 163 work was supported by the Wellcome Trust [217191/Z/19/Z to Y.M.].

164

## 165 **References**

166 1. Kato H, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA

167 viruses. *Nature* **441**, 101-105 (2006).

- 168 2. Peisley A, *et al.* Cooperative assembly and dynamic disassembly of MDA5 filaments for
- 169 viral dsRNA recognition. *Proc Natl Acad Sci U S A* **108**, 21010-21015 (2011).
- 170 3. Berke IC, Modis Y. MDA5 cooperatively forms dimers and ATP-sensitive filaments upon

171 binding double-stranded RNA. *EMBO J* **31**, 1714-1726 (2012).

- Yu Q, Qu K, Modis Y. Cryo-EM Structures of MDA5-dsRNA Filaments at Different Stages of
   ATP Hydrolysis. *Mol Cell* 72, 999-1012 e1016 (2018).
- 174 5. Yu Q, Herrero Del Valle A, Singh R, Modis Y. MDA5 disease variant M854K prevents ATP-
- dependent structural discrimination of viral and cellular RNA. *Nat Commun* **12**, 6668 (2021).
- Singh R, *et al.* Contrasting functions of ATP hydrolysis by MDA5 and LGP2 in viral RNA
  sensing. *J Biol Chem* **300**, 105711 (2024).
- 178 7. Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: The type I
- 179 interferonopathies, a conceptual overview. *J Exp Med* **213**, 2527-2538 (2016).
- 180 8. Rutsch F, et al. A specific IFIH1 gain-of-function mutation causes Singleton-Merten
- 181 syndrome. *Am J Hum Genet* **96**, 275-282 (2015).

182 9. Rice GI, et al. Genetic and phenotypic spectrum associated with IFIH1 gain-of-function.

183 *Hum Mutat* **41**, 837-849 (2020).

- 184 10. Garau J, et al. Molecular Genetics and Interferon Signature in the Italian Aicardi Goutieres
- 185 Syndrome Cohort: Report of 12 New Cases and Literature Review. J Clin Med 8, 750
- 186 (2019).
- 187 11. Lamborn IT, et al. Recurrent rhinovirus infections in a child with inherited MDA5 deficiency.
- 188 *J Exp Med* **214**, 1949-1972 (2017).
- 189 12. Cananzi M, *et al.* IFIH1 loss-of-function variants contribute to very early-onset inflammatory

190 bowel disease. *Hum Genet* **140**, 1299-1312 (2021).

191 13. Adiliaghdam F, et al. Human enteric viruses autonomously shape inflammatory bowel

disease phenotype through divergent innate immunomodulation. *Sci Immunol* 7, eabn6660(2022).

- 194 14. Smyth DJ, et al. A genome-wide association study of nonsynonymous SNPs identifies a
- type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. *Nat Genet* 38, 617619 (2006).

197 15. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene

implicated in antiviral responses, protect against type 1 diabetes. *Science* 324, 387-389(2009).

200 16. Liu S, et al. IFIH1 polymorphisms are significantly associated with type 1 diabetes and

- 201 IFIH1 gene expression in peripheral blood mononuclear cells. *Hum Mol Genet* 18, 358-365
  202 (2009).
- 17. Vasseur E, *et al.* The selective footprints of viral pressures at the human RIG-I-like receptor
   family. *Hum Mol Genet* 20, 4462-4474 (2011).
- 205 18. Gorman JA, et al. The A946T variant of the RNA sensor IFIH1 mediates an interferon
- program that limits viral infection but increases the risk for autoimmunity. *Nat Immunol* **18**,
- 207 744-752 (2017).

- 208 19. Downes K, *et al.* Reduced expression of IFIH1 is protective for type 1 diabetes. *PLoS One*209 5, (2010).
- 210 20. de Azevedo Silva J, et al. Meta-analysis of STAT4 and IFIH1 polymorphisms in type 1
- 211 diabetes mellitus patients with autoimmune polyglandular syndrome type III. Genet Mol Res
- 212 **14**, 17730-17738 (2015).
- 213 21. Jermendy A, Szatmari I, Korner A, Szabo AJ, Toth-Heyn P, Hermann R. Association
- between interferon-induced helicase (IFIH1) rs1990760 polymorphism and seasonal
- variation in the onset of type 1 diabetes mellitus. *Pediatr Diabetes* **19**, 300-304 (2018).
- 216 22. Shigemoto T, Kageyama M, Hirai R, Zheng J, Yoneyama M, Fujita T. Identification of loss
- 217 of function mutations in human genes encoding RIG-I and MDA5: implications for
- 218 resistance to type I diabetes. *J Biol Chem* **284**, 13348-13354 (2009).
- 219 23. Singh R, *et al.* Molecular basis of pathogenesis and protection from type 1 diabetes by loss
  220 of function MDA5 variants. *bioRxiv*, (2024).
- 221 24. Yeung WC, Rawlinson WD, Craig ME. Enterovirus infection and type 1 diabetes mellitus:
- systematic review and meta-analysis of observational molecular studies. *BMJ* 342, d35
- 223 (2011).
- 224 25. Hyoty H, Taylor KW. The role of viruses in human diabetes. *Diabetologia* 45, 1353-1361
  225 (2002).
- 226 26. Wang JP, Cerny A, Asher DR, Kurt-Jones EA, Bronson RT, Finberg RW. MDA5 and MAVS
- 227 mediate type I interferon responses to coxsackie B virus. *J Virol* **84**, 254-260 (2010).
- 228 27. Visser LJ, *et al.* Essential Role of Enterovirus 2A Protease in Counteracting Stress Granule
- Even 229 Formation and the Induction of Type I Interferon. *J Virol* **93**, (2019).
- 230 28. Hato SV, *et al.* The mengovirus leader protein blocks interferon-alpha/beta gene
- transcription and inhibits activation of interferon regulatory factor 3. *Cell Microbiol* 9, 2921-
- 232 2930 (2007).

- 233 29. Dou Y, Yim HC, Kirkwood CD, Williams BR, Sadler AJ. The innate immune receptor MDA5
  234 limits rotavirus infection but promotes cell death and pancreatic inflammation. *EMBO J* 36,
  235 2742-2757 (2017).
- 236 30. Axelrad JE, *et al.* Gastrointestinal Infection Increases Odds of Inflammatory Bowel Disease
- in a Nationwide Case-Control Study. *Clin Gastroenterol Hepatol* **17**, 1311-1322 e1317
- 238 (2019).
- 31. Robertson CC, *et al.* Fine-mapping, trans-ancestral and genomic analyses identify causal
  variants, cells, genes and drug targets for type 1 diabetes. *Nat Genet* 53, 962-971 (2021).
- 241 32. Liu JZ, *et al.* Association analyses identify 38 susceptibility loci for inflammatory bowel
- disease and highlight shared genetic risk across populations. *Nat Genet* **47**, 979-986
- 243 (2015).
- 33. Tsoi LC, *et al.* Large scale meta-analysis characterizes genetic architecture for common
   psoriasis associated variants. *Nat Commun* 8, 15382 (2017).
- 246 34. Karczewski KJ, et al. Pan-UK Biobank GWAS improves discovery, analysis of genetic
- 247 architecture, and resolution into ancestry-enriched effects. *bioRxiv*,
- 248 2024.2003.2013.24303864 (2024).
- 249 35. Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to variable selection
- 250 in regression, with application to genetic fine mapping. *J R Stat Soc Series B Stat Methodol*
- **82**, 1273-1300 (2020).
- 252 36. Zou Y, Carbonetto P, Wang G, Stephens M. Fine-mapping from summary data with the
  253 "Sum of Single Effects" model. *PLoS genetics* **18**, e1010299 (2022).
- 37. Wallace C. Statistical testing of shared genetic control for potentially related traits. *Genet Epidemiol* **37**, 802-813 (2013).
- 256
- 257



Fig. 1. Manhattan plots of fine-mapped variants for five diseases. Colored circles indicate the fine mapping sets identified, and colored text labels the most likely causal SNP in each set, selected due its known function on MDA5. Known loss-of-function SNPs that were not in any fine mapping set are marked with "x" and a black label. Lower right, minor allele frequency (MAF) and function of fine-mapped SNPs.



264 265 Figure 2. GWAS meta-analysis of loss-of-function MDA5 variants. (a) Effect sizes expressed in terms 266 of the odd ratio for selected MDA5 loss-of-function variants. <sup>‡</sup>Because rs35337543 was only available in 267 two GWAS datasets, rs72871627 ( $r^2 = 0.973$ ) was used as a tag for rs35337543. EAF, effect allele frequency. Error bars, SEM. ns, P > 0.05; \*, P < 0.05; \*\*, P < 0.01; \*\*\*, P < 0.001; \*\*\*\*, P < 5×10<sup>-8</sup> 268 269 (genome-wide significance), where P is the Bonferroni-adjusted P value from marginal association 270 analysis. CV, likely causal variant present in a credible set in fine-mapping analysis. R843H was included 271 in fine-mapping analysis but excluded from marginal association analysis. See **Table 1**. (b) Odds ratio 272 plot for variants and diseases in (a). (c) Estimated effect sizes in hypothyroidism compared to the other 273 diseases. Hypothyroidism was selected because it was the largest dataset for which all SNPs were 274 available. Dashed lines, identity and negative identity lines. 275

Variant	SNP	Location	Allele	EAF	Disease	InOR $\pm$ std. err.	OR	Р	PBonferroni	Causal‡
1923V	rs35667974	2:162268127	T>C	0.022	T1D	$\textbf{-0.493} \pm 0.062$	0.611	1.21×10 <sup>-15</sup>	2.91×10 <sup>-14</sup>	Т
					Psoriasis	$-0.440 \pm 0.129$	0.644	6.68×10 <sup>-4</sup>	0.0160	F
					Hypothyr.	$-0.254 \pm 0.038$	0.776	2.98×10 <sup>-11</sup>	7.16×10 <sup>-10</sup>	Т
					Crohn's	$0.121\pm0.046$	1.129	8.08×10 <sup>-3</sup>	0.1938	F
					UC	$0.276\pm0.046$	1.318	1.94×10 <sup>-9</sup>	4.64×10 <sup>-8</sup>	Т
Splice1	rs35732034	2:162268086	C>T	0.010	Psoriasis	$\textbf{-0.693} \pm 0.253$	0.500	6.25×10 <sup>-3</sup>	0.1500	F
					T1D	-0.464 ± 0.083	0.629	2.29×10 <sup>-8</sup>	5.50×10 <sup>-7</sup>	Т
					Hypothyr.	$-0.230 \pm 0.056$	0.794	4.47×10 <sup>-5</sup>	1.07×10 <sup>-3</sup>	F
					UC	$0.180\pm0.067$	1.197	7.70×10 <sup>-3</sup>	0.1848	F
					Crohn's	$0.226\pm0.064$	1.253	4.15×10 <sup>-4</sup>	9.96×10⁻³	F
Splice2*	rs72871627	2:162280432	A>G	0.015	Psoriasis	-0.541 ± 0.200	0.582	6.81×10 <sup>-3</sup>	0.1634	F
					T1D	$-0.458 \pm 0.073$	0.633	4.19×10 <sup>-10</sup>	1.00×10 <sup>-8</sup>	Т
					Hypothyr.	$-0.253 \pm 0.046$	0.777	2.94×10 <sup>-8</sup>	7.05×10 <sup>-7</sup>	Т
					Crohn's	$0.072\pm0.056$	1.074	0.1990	1	F
					UC	$0.308\pm0.054$	1.360	1.19×10⁻ <sup>8</sup>	2.85×10 <sup>-7</sup>	Т
Splice2	rs35337543	2:162279995	C>G	0.015	T1D	$\textbf{-0.458} \pm 0.073$	0.633	4.19×10 <sup>-10</sup>	ND	Т
					Hypothyr.	$-0.236 \pm 0.045$	0.790	1.51×10 <sup>-7</sup>	ND	Т
E627*	rs35744605	2:162277580	C>A	0.007	Hypothyr.	$-0.273 \pm 0.068$	0.761	5.63×10 <sup>-5</sup>	1.35×10 <sup>-3</sup>	F
					Psoriasis	$-0.210 \pm 0.372$	0.810	0.5717	1	F
T946A	rs1990760	2:162267541	T>C	0.389	Psoriasis	$\textbf{-0.192} \pm 0.034$	0.825	1.95×10 <sup>-8</sup>	4.68×10 <sup>-7</sup>	Т
					T1D	$-0.132 \pm 0.013$	0.876	5.57×10 <sup>-24</sup>	1.34×10 <sup>-22</sup>	Т
					Hypothyr.	$-0.080 \pm 0.011$	0.923	5.61×10 <sup>-13</sup>	1.35×10 <sup>-11</sup>	Т
					Crohn's	$0.053\pm0.013$	1.055	3.36×10⁻⁵	8.07×10 <sup>-4</sup>	F
					UC	$0.086\pm0.013$	1.089	1.78×10 <sup>-10</sup>	4.27×10 <sup>-9</sup>	Т
R843H	rs3747517	2:162272314	C>T	0.276	T1D	-0.111 ± 0.014	0.895	2.94×10 <sup>-15</sup>	ND	F
					Psoriasis	$-0.103 \pm 0.035$	0.903	3.72×10 <sup>-3</sup>	ND	F
					Hypothyr.	$-0.068 \pm 0.012$	0.934	1.85×10 <sup>-8</sup>	ND	F
					Crohn's	$0.030\pm0.014$	1.031	0.0301	ND	F
					UC	$0.051\pm0.014$	1.053	3.85×10 <sup>-4</sup>	ND	F
N160D	rs74162075	2-162310909	T>C	0.001	Psoriasis	-2.057 ± 0.811	0.128	0.0111	0.2674	F
					Hypothyr.	$-0.270 \pm 0.133$	0.763	0.0427	1	F

# Table 1. Marginal association and fine-mapping analysis results.

277 EAF, effect allele frequency; OR, odds ratio.

\*rs72871627 was used as a tag of rs35337543 because the latter was not available in all GWAS
 datasets.

<sup>280</sup> <sup>‡</sup>Causality was inferred from presence of the SNP in a credible set in fine mapping analysis.

281 Dashed lines indicate that the SNPs above and below the line are in LD with each other.